Managing patients with invasive Salmonella infections in lowresource areas continues to be problematic. In addition to challenges with clinical diagnosis, 11 conventional diagnosis by blood culture is insensitive, slow and may not be available, 8 and so can rarely inform acute management. Developing rapid diagnostic tests for invasive Salmonella infections has proved challenging. For invasive non-typhoidal Salmonella, comorbidities and late presentation contribute to high case fatality ratios. 12 Multiple-drug resistant non-typhoidal and typhoidal Salmonella is established in Africa. 13 The emergence of decreased fluoroquinolone susceptibility among typhoidal Salmonella 14 and extended-spectrum cephalosporin resistance among nontyphoidal Salmonella 15 threaten existing regimens for management of sepsis, leaving limited antimicrobial treatment options and, potentially, leading to worse outcomes. Therefore, the continuing emergence of antimicrobial resistance among invasive Salmonella should focus the attention of the research and public health community on strategies for control and prevention.
Despite many decades of research we have only a rudimentary understanding of sources, modes of transmission and risk factors for infection that, alongside disease burden estimates, are crucial to the design of non-vaccine prevention programs. Human feces are the ultimate source of typhoidal Salmonella, and the host risk factors for invasive non-typhoidal Salmonella, including malaria, malnutrition and HIV, are well appreciated. 12 Research in industrialized nations indicate that non-human vertebrate animals are the major reservoir of non-typhoidal Salmonella and that transmission to humans is usually via the consumption of foods of animal origin, produce contaminated by animal feces, and occasionally via water or direct contact with animals and their environments. 16 However, genomic studies suggest humanhost adaptation of epidemic invasive non-typhoidal Salmonella in Africa raising the possibility of transmission cycles that do not involve animals. 17 An understanding of the relative contribution of waterborne, foodborne and other routes of transmission of both typhoidal and non-typhoidal Salmonella remains elusive. Although the few risk factor studies that have been conducted in Africa have provided few clues, novel molecular epidemiological tools implemented together with high quality field epidemiology now provide an exciting opportunity to make real progress. Therefore, renewed field epidemiologic efforts on invasive Salmonella in Africa are needed to inform and direct non-vaccine prevention and control efforts.
Typhoid fever vaccines have not been widely used in endemic countries, including in Africa. Newer conjugate typhoid vaccines offer protection earlier in life 18 and for longer durations 19 than established vaccines, but the lack of a commercial incentive has probably contributed to a long delay in their implementation. 20 Furthermore, key questions remain unanswered about how to use them. What is the best timing of vaccination and how many doses will be needed? Will they provide herd protection? Should vaccines be used widely or targeted to high-risk segments of the population? If targeted, how would high-risk groups be identified? Vaccine development efforts for non-typhoidal Salmonella and Salmonella Paratyphi A have lagged far behind those for Salmonella Typhi. To identify an integrated vaccine solution to invasive Salmonella infections, progress needs to be made across a wider spectrum of responsible Salmonella serovars. Presently it is unclear whether an integrated solution to vaccine prevention of invasive Salmonella infections lies in conjugate vaccines stimulating antibodies to multiple surface antigens, including Vi and relevant O and H antigens, through strategies using new live-attenuated vaccines, targeting highly conserved proteins or using outer membrane fragments. 21 Whatever the way forward in terms of antigen selection and vaccine design, vaccines implemented in Africa will have to overcome a number of challenges, particularly for invasive nontyphoidal Salmonella. These include the influence of host factors such as young age, HIV-related immunosuppression, malnutrition and malaria 12 on vaccine efficacy. Much remains to be done to address invasive Salmonella infections in Africa. Developing and refining estimates of the burden of illness and death will be vital for this group of infections to be more widely appreciated. A robust understanding of the disease burden envelopes will allow projection of the scale of potential impact of interventions. Fundamental epidemiologic research is needed to provide an evidence base for selection of both vaccine and nonvaccine interventions tailored to African countries. Progress with existing potentially highly effective vaccines for typhoid fever will require development of the investment case, a funding strategy, and progress on where and how they should be used. At the same time, vaccine development efforts that broaden the focus to include non-typhoidal Salmonella and Salmonella serovar Paratyphi A will progress the field towards more integrated vaccine solutions. Invasive Salmonella infections remain an important but under-appreciated infectious diseases problem in Africa. The international research and public health community are only just beginning to appreciate that efforts across the spectrum from fundamental to implementation science are needed if we are to effectively tackle this major infectious diseases problem.
